Immunotherapy Advances

SCIE

国际简称：Immunother Adv 参考译名：免疫疗法进展

主要研究方向：Immunology and Microbiology-Immunology 非预警期刊审稿周期：7 Weeks

《免疫疗法进展》(Immunotherapy Advances)是一本由Oxford University Press出版的以Immunology and Microbiology-Immunology为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

3区中科院分区
Q2 JCR分区
31 年发文量
4.4 IF影响因子
未开放 是否OA
English 出版语言

Immunotherapy Advances is an international academic journal dedicated to the field of immunotherapy, dedicated to publishing the latest research, reviews, and case reports on immunotherapy, providing a platform for researchers, clinicians, and pharmaceutical companies worldwide to exchange and share their latest research findings. The content of the magazine includes basic research on immunotherapy, clinical trials, drug development, vaccine research, cell therapy, gene therapy, and other aspects. These contents cover various aspects of immunotherapy, providing readers with a comprehensive understanding of the field of immunotherapy. In addition, the magazine also focuses on the application of immunotherapy in different diseases. The goal of the journal is to become an authoritative journal in the field of immunotherapy, providing a high-quality academic exchange platform for researchers worldwide. By publishing cutting-edge research and reviews, this journal contributes to advancing the field of immunotherapy and providing better treatment options for patients.

[ 查看全部 ]

投稿咨询加急咨询

Immunotherapy Advances期刊信息

ISSN：2732-4303
出版语言：English
是否OA：未开放
出版地区：United Kingdom
是否预警：否
出版商：Oxford University Press
Gold OA文章占比：100.00%
研究类文章占比：58.06%

Immunotherapy Advances CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

7.6

1.504

1.093

学科类别	分区	排名	百分位
大类：Immunology and Microbiology 小类：Immunology	Q2	64 / 243	73%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Immunotherapy Advances中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	IMMUNOLOGY 免疫学	3区

Immunotherapy Advances JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	ESCI	Q2	63 / 183	65.8
学科：IMMUNOLOGY	ESCI	Q3	105 / 183	42.9

Immunotherapy Advances历年数据统计

影响因子

中科院分区

Immunotherapy Advances中国学者发文选摘

1、Heterogeneity of regulatory B cells in autoimmune diseases: implications for immune equilibrium and therapeutic strategie
Author: Yan, Haozhen; He, Jing; Lin, Xiang

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf020
2、High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with Immune checkpoint inhibitor
Author: Zhao, Rui; Wang, Weihao; Wang, Jingliang; Wang, Yahui; Pan, Liying; Ran, Pancen; Luan, Fang; Fu, Guobin

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf019
3、Abnormal glucose and lipid metabolism promotes disrupted differentiation of T and B cell subsets in Behçet's diseas
Author: Li, Minghao; Li, Ping; Wang, Xin; Wang, Lijie; Gao, Guanmin; Jiang, Guosheng; Liu, Tingting; Lin, Wei

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf010
4、M2 macrophages promote IL-10+B-cell production and alleviate asthma in mic
Author: Yu, Baichao; Wang, Xueqi; Zheng, Yongkun; Wang, Wenjun; Cheng, Xiaoqin; Cao, Yue; Wei, Mingxing; Fu, Ying; Chu, Yiwei; Wang, Luman

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf007
5、Harnessing monocyte dynamics for treatment of multiple sclerosis; insights from experimental model studie
Author: Bibi, Aqsa; Yu, Zhenjiang; Cui, Lv; Yang, Guiwen

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf003
6、Intra-tumoural RAMP1+B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinom
Author: Zhang, Hongyu; Zhang, Yuchen; Zhou, Pingjing; Guo, Yifan; Jiang, Liqun; Gu, Jie

Journal: IMMUNOTHERAPY ADVANCES. 2025; Vol. 5, Issue 1, pp. -. DOI: 10.1093/immadv/ltaf012